Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michael H. Goldstein | M | 57 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | 2 Jahre |
Christine Z. McCauley | F | 59 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | - |
Richard Lindstrom | M | 76 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | - |
Bill Link | M | 78 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | - |
Thomas Frinzi | M | 68 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | 4 Jahre |
Andrew ElBardissi | M | 42 |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | - |
Patrick P. Lally | M | - |
Aurion Biotech, Inc.
Aurion Biotech, Inc. Medical/Nursing ServicesHealth Services Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 7 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Greg Kunst
- Persönliches Netzwerk